<body><a name="drugname"></a><table class="topbox" width="100%">
<tr>
<td><span class="topboxgenname">TIROFIBAN HYDROCHLORIDE</span><br/>(tir-o-fi'ban)<br/><span class="topboxtradename">Aggrastat<br/></span><b>Classifications:</b> <span class="classification">blood formers, coagulators, and anticoagulants</span>; <span class="classification">antiplatelet agent</span>; <span class="classification">glycoprotein iib/iiia receptor inhibitor</span><br/><b>Prototype: </b>Abciximab<br/><b>Pregnancy Category: </b>B<br/></td>
</tr>
</table>
<h1><a name="avail">Availability</a></h1>
<p>250 mcg/mL, 50 mcg/mL injection</p>
<h1><a name="action">Actions</a></h1>
<p>Antiplatelet agent that binds to the glycoprotein IIb/IIIa receptor of platelets.</p>
<h1><a name="therapef">Therapeutic Effects</a></h1>
<p>Inhibits platelet aggregation. Effectiveness indicated by minimizing thrombotic events during treatment of acute coronary
         syndrome.
      </p>
<h1><a name="uses">Uses</a></h1>
<p>Acute coronary syndromes (unstable angina, MI).</p>
<h1><a name="contrain">Contraindications</a></h1>
<p>Active internal bleeding within 30 d; acute pericarditis; aortic dissection; concurrent use with another glycoprotein IIb/IIIa
         receptor inhibitor (e.g., eptifibatide, abciximab); history of aneurysm or AV malformation; history of intracranial hemorrhage
         or neoplasm; hypersensitivity to tirofiban; major surgery or trauma within 3 d; stroke within 30 d; history of hemorrhagic
         stroke; thrombocytopenia following administration of tirofiban; pregnancy (category B); lactation.
      </p>
<h1><a name="precaution">Cautious Use</a></h1>
<p>Concomitant use with thrombolytic agents or drugs that cause hemolysis; hemorrhagic retinopathy; platelet count 3; severe renal insufficiency. Safety and efficacy in children 
      </p><h1><a name="rtedsg">Route &amp; Dosage</a></h1>
<table cellpadding="4" cellspacing="0" class="rdbox" width="100%">
<tr>
<td><span class="indicationtitle">Acute Coronary Syndromes</span><br/><span class="rdage">Adult:</span> <span class="rdroute">IV Loading Dose</span> 0.4 mcg/kg/min times 30 min <span class="rdroute">IV Maintenance Dose</span> 0.1 mcg/kg/min for 1224 h after angioplasty or arteriectomy<br/><br/><span class="impairmenttitle">Renal Impairment</span><br/>Cl<sub>cr</sub> <br/></td>
</tr>
</table>
<h1><a name="admintn">Administration</a></h1>
<table cellpadding="4" cellspacing="0" class="ivbox" width="100%">
<tr>
<td><span class="ivtitle">Intravenous</span><p><span class="routemethod">PREPARE:</span> <span class="methodtype">IV Infusion:</span> Withdraw 100 mL from a 500-mL bag of NS or D5W and replace with 100 mL of tirofiban HCl injection. If a 250-mL IV bag is used,
                  withdraw 50 mL of IV solution and replace with 50 mL of tirofiban injection. Either preparation yields 50 mcg/mL. Mix well
                  before infusing. Note: Commercially premixed IV tirofiban solutions are available.  
               </p>
<p><span class="routemethod">ADMINISTER:</span> <span class="methodtype">IV Infusion:</span> An initial loading dose of 0.4 mcg/kg/min for 30 min is usually followed by a maintenance infusion of 0.1 mcg/kg/min.  
               </p>
<p><span class="routemethod">INCOMPATIBILITIES</span> <span class="incompattype">Y-site:</span>
<b>Diazepam.</b>
</p>
</td>
</tr>
</table>
<ul>
<li>Discard unused IV solution 24 h following start of infusion. </li>
<li>Store unopened containers at 15°30° C (59°86° F). Do not freeze and protect from light.</li>
</ul>
<h1><a name="adverse">Adverse Effects (<img src="../images/special/greaterorequal.gif"/>1%)</a></h1><span class="typehead"> Body as a Whole:</span> Edema, swelling, pelvic pain, vasovagal reaction, leg pain. <span class="typehead">CNS:</span> Dizziness. <span class="typehead">CV:</span> Bradycardia, <span class="speceff-life">coronary artery dissection</span>. <span class="typehead">GI:</span> GI bleeding. <span class="typehead">Hematologic:</span>
<span class="speceff-common">Bleeding</span> (<span class="speceff-life">major bleeding</span>), anemia, thrombocytopenia. <span class="typehead">Skin:</span> Sweating. 
      <h1><a name="interactions">Interactions</a></h1><span class="typehead">Drug:</span> Increased risk of bleeding with <span class="classification">anticoagulants</span>, <span class="classification">nsaid</span>s, <span class="classification">salicylates</span>, <span class="classification">antiplatelet agents</span>.  <span class="typehead">Herbal:</span>
<b>Feverfew,</b>
<b>garlic,</b>
<b>ginger,</b>
<b>ginkgo,</b>
<b>horse chestnut</b> may increase risk of bleeding. 
      <h1><a name="pharmaks">Pharmacokinetics</a></h1><span class="typehead">Duration:</span> 48 h after stopping infusion. <span class="typehead">Distribution:</span> 65% protein bound. <span class="typehead">Metabolism:</span> Minimally metabolized. <span class="typehead">Elimination:</span> 65% excreted in urine, 25% in feces. <span class="typehead">Half-Life:</span> 2 h. 
      <h1><a name="nursing"><span class="implictitle">Nursing Implications</span></a></h1>
<p><span class="adeffecttitle">Assessment &amp; Drug Effects</span></p>
<ul>
<li>Lab tests: Monitor platelet count, Hgb and Hct before treatment, (within 6 h of infusing loading dose), and frequently throughout
            treatment; monitor aPTT, INR, and ACT.
         </li>
<li>Withhold drug and notify physician if thrombocytopenia (platelets 
         </li><li>Monitor carefully for and immediately report S&amp;S of internal or external bleeding.</li>
<li>Wait at least 34 h after heparin is stopped and until ACT 
         </li><li>Minimize unnecessary invasive procedures and devices to reduce the risk of bleeding.</li>
</ul>
<p><span class="eductitle">Patient &amp; Family Education</span></p>
<ul>
<li>Report unexplained pelvic or abdominal pain.</li>
</ul>
<hr/>
<p><span class="footer">Common adverse effects in <i>italic</i>, life-threatening effects <u>underlined</u>; generic names in <b>bold</b>; classifications in <small>SMALL CAPS</small>; <img border="0" src="../images/maple.gif"/> Canadian drug name; <img border="0" src="../images/pr.gif"/> Prototype drug</span></p>
</body>